ICH E6 (R3) Guideline on good clinical practice (GCP)
International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use
GOOD CLINICAL PRACTICE (GCP) E6(R3) Step 5
23 January 2025. Date for coming into effect 23 July 2025
ICH E6(R3) introduces innovative provisions designed to apply across various types and settings of clinical trials, ensuring continued relevance in the face of ongoing technological and methodological advancements. This guideline provides a new language to facilitate innovations in clinical trial design, technology, and operational approaches. It encourages a risk-based and proportionate approach to conducting clinical trials, promoting fit-for-purpose solutions. It fosters transparency through clinical trial registration and result reporting and offers additional guidance to enhance the informed consent process.
The overarching principles and Annex 1, adopted by ICH and CHMP, came into effect on 23 July 2025.
With the public consultation now concluded, the Annex 2 is expected to be finalised later in 2025.
I. INTRODUCTION
II. PRINCIPLES OF ICH GCP
III. ANNEX 1
1. INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
2. INVESTIGATOR
3. SPONSOR
4. DATA GOVERNANCE – INVESTIGATOR AND SPONSOR
Appendix A. INVESTIGATOR’S BROCHURE
Appendix B. CLINICAL TRIAL PROTOCOL AND PROTOCOL AMENDMENT(S)
Appendix C. ESSENTIAL RECORDS FOR THE CONDUCT OF A CLINICAL TRIAL
GLOSSARY
© European Medicines Agency, 2025. Reproduction is authorised provided the source is acknowledged.
Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
Clinical Research News
Upcoming Clinical Trials
-
National Taiwan University HospitalNot yet recruiting
-
SCRI Development Innovations, LLCPfizerNot yet recruitingMultiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma (MM) | Multiple Myeloma Refractory
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingChronic Obstructive Pulmonary Disease (COPD) | DyspneaFrance
-
Stanford UniversityNot yet recruiting
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingHPV Vaccination | HPV-related CancersUnited States
-
National Institute of Diabetes and Digestive and...Not yet recruitingHealthy VolunteerUnited States
-
National Institute on Drug Abuse (NIDA)Not yet recruitingHIV | Substance Use DisorderUnited States
-
Zhejiang UniversityNot yet recruitingPancreatitis | Cholelithiasis | Obstructive Jaundice | Choledocholithiasis With Cholecystitis With ObstructionChina
-
Verrica Pharmaceuticals Inc.CMIC Co, Ltd. Japan; Medidata Solutions; Veeva Systems; Canfield Scientific Inc.; Torii Pharmaceutical Co. Ltd... and other collaboratorsNot yet recruitingWarts | Human Papilloma Virus (HPV) | Common Warts | Common Warts (Verruca Vulgaris)United States
-
University of Southern DenmarkRecruitingShared Decision MakingDenmark
-
Universidad Complutense de MadridNot yet recruiting
-
Jie LiRecruitingAnhedonia | Late-Life DepressionChina
Clinical Research Jobs
-
Philippines - Manila
-
United Kingdom - Tranent
-
Brazil - São Paulo - São Paulo
-
Canada - Ontario - OntarioCanada - Québec - Quebec
-
Romania - Bucharest
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China